
FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.
VWR International has signed a global distribution agreement with Thermo Fisher Scientific.
p>
Thermo Fisher represents one of VWR's most important global suppliers with products supporting all of VWR's customer segments, including pharmaceutical, biotech, industrial, educational, governmental and healthcare.
Source:






